

FAX OR MAIL this form to:
 La Medicaid Rx PA Operations
 ULM School of Pharmacy
 1800 Bienville Drive
 Monroe, LA 71201-3765
 FAX 866-RX PA FAX
 FAX 866-797-2329

State of Louisiana
 Department of Health and Hospitals
 Bureau of Health Services Financing
 Louisiana Medicaid Prescription Prior Authorization Program
REQUEST FOR PRESCRIPTION OVERRIDE

Form: Rx PA16
 Issue Date: 3/01/2013
 Revised Date: 2/12/2015

Voice Phone:
 866-730-4357

Please type or print legibly. Incomplete forms will not be approved.

Date of Request		Number of Fax Pages	
Prescribing Provider Information		Recipient Information	
Name (Last, First)		Name (Last, First)	
LA Medicaid Prescribing Provider Number / NPI		LA Medicaid CCN or Recipient Number	
Provider Specialty		Date of Birth (mm/dd/yy)	
Call-Back Phone Number (include area code)		Recipient Weight (kg)	Recipient Height (ft / in)
FAX Number (Include area code)		Medication Allergies	
Office Contact Name		EPSDT Support Coordinator (Name / Address) (optional)	
Requested Drug Information			
Initiation of Therapy <input type="checkbox"/>		Continuation of Therapy <input type="checkbox"/>	
Drug Name	Drug Strength	Dosage Form	Dosage Interval (sig)
Diagnosis Code [relevant for this request]		Diagnosis Description	Quantity

This request is for:

For duration of therapy override

Diagnosis	
Medical Justification	

For early refill override

<input type="checkbox"/> Medication lost	<input type="checkbox"/> Physician changed dosage
<input type="checkbox"/> Medication destroyed	<input type="checkbox"/> Medication stolen
<input type="checkbox"/> Patient going out of town for period greater than the day's supply remaining of the previous refill	

Please attach supporting documentation

For maximum unit / maximum cost / maximum dose / quantity limit override

Diagnosis	
Medical Justification	

For therapeutic duplication

Diagnosis	
Reason for request	<input type="checkbox"/> Strength / dosage change* <input type="checkbox"/> Titration and concomitant therapy**
Drug name and strength	Qty _____ Stop date _____
Drug name and strength	Qty _____ Stop date _____
Reason for change	

* Stop date is required for strength / dosage change

** Attach medical justification if both drugs are to be continued (titration / concomitant therapy)

Practitioner Signature: _____

(If a signature stamp is used, then the prescribing practitioner must initial the signature.)

CONFIDENTIAL NOTICE

The documents accompanying this facsimile transmission may contain confidential information which is legally privileged. The information is intended only for the use of the individual or entity to which it is addressed. If you are not the intended recipient you are hereby notified that any review, disclosure/re-disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy this information.

Louisiana Fee-For-Service (FFS) Medicaid Opioid Analgesic Treatment Worksheet

This worksheet must be completed in full and submitted with the Request for Prescription Override (RXPA16) form.
Provide supporting documentation where applicable.

Recipient Name:	Medicaid Recipient ID #	Recipient DOB:
Prescriber Name:	Prescriber Specialty:	Medicaid Provider ID # or NPI#:
Call-Back Phone#:	Office Fax#:	Office Contact:

DRUG INFORMATION

DRUG NAME/DOSAGE FORM _____ STRENGTH _____
 DIRECTIONS _____ QUANTITY REQUESTED _____
 REQUEST IS FOR: INITIATION OF THERAPY CONTINUATION OF THERAPY

TREATMENT INFORMATION

1. This medication is being used for: acute pain chronic pain
2. Diagnoses for which the opioid is prescribed in greater than a 15-day supply: _____
3. Explain in detail why the opioid quantity exceeds a 15-day supply: _____
4. List other treatments that have been tried for this condition, both pharmacological and non-pharmacological: _____
5. List other opioid analgesics that are to be used concurrently with the requested medication for treatment of pain (if applicable): _____

PRESCRIBER ATTESTATION

6. The prescriber attests to the following:

YES	NO	ATTESTATION
		A complete assessment for pain and function was performed for this patient.
		The patient's risk for opioid misuse or abuse has been assessed.
		The PDMP (Prescription Drug Monitoring Program) will be accessed each time a new prescription is written for this patient.
		A treatment plan which includes goals of therapy for both pain and function has been developed for this patient.
		Criteria for failure of the opioid trial and for stopping or continuing the opioid has been established and explained to the patient.
		Benefits and potential harms of opioid use have been discussed with this patient. In addition, risks of combining opioids with other central nervous system depressants such as benzodiazepines, alcohol, other sedatives, illicit drugs such as heroin, or other opioids have been discussed with this patient.
		An Opioid Treatment Agreement signed by both the patient and prescriber is on file.

IF NO FOR ANY OF THE ABOVE, PLEASE EXPLAIN:

YES	NO	ATTESTATION
		Prescriber attests that the patient's cumulative Morphine Equivalent Dose for all current meds is less than 90MED/day.*

IF NO, GIVE MEDICAL JUSTIFICATION FOR THE NEED FOR MORPHINE EQUIVALENT DOSE EQUAL TO OR EXCEEDING 90MED/DAY:

**CDC guidelines recommend that prescribers carefully reassess evidence of individual benefits and risks when considering increasing Morphine Equivalent Dosage to \geq 50MED/day, and that prescribers avoid increasing dosage to \geq 90MED/day or carefully justify the decision to titrate dosage to \geq 90MED/day. Various online Morphine Equivalent Dose calculators are available.*

ADDITIONAL INFORMATION

7. Is the patient currently a resident in a long-term care facility? Yes No
 If Yes, Facility name: _____ Facility address: _____
 Facility phone number: _____

Prescriber's Signature _____ Date _____
(If a signature stamp is used, then the prescribing practitioner must initial the stamp.)

CONFIDENTIALITY NOTICE
 The documents accompanying this facsimile transmission may contain confidential information which is legally privileged. The information is intended only for the use of the individual or entity to which it is addressed. If you are not the intended recipient you are hereby notified that any review, disclosure/re-disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy this information.